MedPath

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Generalized Anxiety Disorder
Interventions
Drug: Placebo
Registration Number
NCT01844115
Lead Sponsor
Forest Laboratories
Brief Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
415
Inclusion Criteria
  • Male or female outpatient, 18-70 years of age
  • Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder
  • Minimum score of 20 on Hamilton Rating Scale for Anxiety
Exclusion Criteria
  • Women who are pregnant or who will be breastfeeding during the study

  • Patients with a history of:

    1. Any manic or hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic or mixed episode
    2. Any depressive episode with psychotic or catatonic features
    3. Panic disorder with or without agoraphobia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboDose-matched placebo tablets, oral administration
VilazodoneVilazodoneVilazodone tablets, oral administration
Primary Outcome Measures
NameTimeMethod
Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreBaseline to Week 8

The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in the Sheehan Disability Scale (SDS) Total ScoreBaseline to Week 8

The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe).

Trial Locations

Locations (36)

Forest Investigative Site 023

🇺🇸

Birmingham, Alabama, United States

Forest Investigative Site 013

🇺🇸

Phoenix, Arizona, United States

Forest Investigative Site 001

🇺🇸

Costa Mesa, California, United States

Forest Investigative Site 026

🇺🇸

Rancho Mirage, California, United States

Forest Investigative Site 030

🇺🇸

Bradenton, Florida, United States

Forest Investigative Site 031

🇺🇸

Dallas, Texas, United States

Forest Investigative Site 032

🇺🇸

Orlando, Florida, United States

Forest Investigative Site 005

🇺🇸

Cherry Hill, New Jersey, United States

Forest Investigative Site 025

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 015

🇺🇸

Albuquerque, New Mexico, United States

Forest Investigative Site 010

🇺🇸

Brooklyn, New York, United States

Forest Investigative Site 016

🇺🇸

Bellevue, Washington, United States

Forest Investigative Site 024

🇺🇸

Seattle, Washington, United States

Forest Investigative Site 002

🇺🇸

Cedarhurst, New York, United States

Forest Investigative Site 004

🇺🇸

Mount Kisco, New York, United States

Forest Investigative Site 017

🇺🇸

Sherman Oaks, California, United States

Forest Investigative Site 035

🇺🇸

Jacksonville, Florida, United States

Forest Investigative Site 021

🇺🇸

West Palm Beach, Florida, United States

Forest Investigative Site 018

🇺🇸

Decatur, Georgia, United States

Forest Investigative Site 022

🇺🇸

Hoffman Estates, Illinois, United States

Forest Investigative Site 014

🇺🇸

Berlin, New Jersey, United States

Forest Investigative Site 019

🇺🇸

Dayton, Ohio, United States

Forest Investigative Site 003

🇺🇸

New York, New York, United States

Forest Investigative Site 020

🇺🇸

New York, New York, United States

Forest Investigative Site 037

🇺🇸

Allentown, Pennsylvania, United States

Forest Investigative Site 011

🇺🇸

Media, Pennsylvania, United States

Forest Investigative Site 012

🇺🇸

Herndon, Virginia, United States

Forest Investigative Site 008

🇺🇸

Portland, Oregon, United States

Forest Investigative Site 028

🇺🇸

Brooklyn, New York, United States

Forest Investigative Site 036

🇺🇸

Beverly Hills, California, United States

Forest Investigative Site 009

🇺🇸

Oceanside, California, United States

Forest Investigative Site 034

🇺🇸

Sherman Oaks, California, United States

Forest Investigative Site 029

🇺🇸

Gainesville, Florida, United States

Forest Investigative Site 007

🇺🇸

New York, New York, United States

Forest Investigative Site 027

🇺🇸

Bronx, New York, United States

Forest Investigative Site 033

🇺🇸

Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath